Moreover, we showed that HSP90 and mTOR inhibitors can be considered as an alternative therapeutic approach in naïve and resistant to ALK inhibitors ALK+ ALCL patients. The gene discussed is MTOR; the disease is anaplastic large cell lymphoma.